Ipsen S.A. (EPA:IPN)
France · Delayed Price · Currency is EUR | Market Cap | 10.90B |
| Revenue (ttm) | 3.76B |
| Net Income (ttm) | 447.90M |
| Shares Out | 82.10M |
| EPS (ttm) | 5.37 |
| PE Ratio | 24.72 |
| Forward PE | 11.48 |
| Dividend | 1.40 (1.05%) |
| Ex-Dividend Date | Jun 4, 2025 |
| Volume | 72,252 |
| Average Volume | 91,951 |
| Open | 134.00 |
| Previous Close | 133.70 |
| Day's Range | 132.30 - 134.10 |
| 52-Week Range | 87.95 - 138.00 |
| Beta | 0.20 |
| RSI | 63.88 |
| Earnings Date | Feb 12, 2026 |
About Ipsen
Ipsen S.A., a biopharmaceutical company, develops and commercializes medicines in the areas of oncology, rare disease, and neuroscience worldwide. Its oncology products include Somatuline for the treatment of neuroendocrine tumors and acromegaly; Cabometyx, a tyrosine kinase inhibitor to treat second line pancreatic and extra-pancreatic neuroendocrine tumors; Onivyde, an irinotecan liposome injection for the treatment of pancreatic cancer; Decapeptyl for the treatment of advanced metastatic prostate cancer; Tazverik, a chemotherapy-free EZH2a i... [Read more]
Full Company ProfileFinancial Performance
In 2024, Ipsen's revenue was 3.57 billion, an increase of 8.11% compared to the previous year's 3.31 billion. Earnings were 345.90 million, a decrease of -46.32%.
Financial StatementsNews
Ipsen S.A. (IPSEY) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow
FDA Boosts Ipsen (IPSEY) with Breakthrough Therapy Designation for AML Treatment
FDA Boosts Ipsen (IPSEY) with Breakthrough Therapy Designation for AML Treatment
Ipsen rises on FDA breakthrough therapy status for blood cancer therapy
FDA Grants Breakthrough Therapy Designation To Ipsen's IPN60340 In Acute Myeloid Leukemia
(RTTNews) - Ipsen (IPSEY, IPN.PA) announced that the U.S. Food and Drug Administration has granted Breakthrough Therapy Designation for IPN60340 in combination with venetoclax and azacitidine (Ven-Aza...
U.S. FDA grants Ipsen's IPN60340 (ICT01) Breakthrough Therapy Designation in first line unfit Acute Myeloid Leukemia
Breakthrough Therapy Designation granted for investigational therapy IPN60340 in combination with venetoclax and azacitidine in first line unfit acute myeloid leukemia PARIS, FRANCE, 13 JANUARY 2026 -...
Ipsen expands early development pipeline with Simcere Zaiming's innovative antibody drug conjugate
Ipsen gains exclusive global rights, outside of Greater China, for development, manufacturing and commercialization of SIM0613, a LRRC15-targeting antibody-drug conjugate SIM0613 is optimally designed...
Simcere Pharma Licenses SIM0613 To Ipsen
(RTTNews) - Simcere Pharmaceutical Group Ltd. (2096.HK, SMHGF), on Monday, announced that a subsidiary, Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd., has entered into an exclusive licensing agreem...
Ipsen S.A. (IPSEY) Q3 2025 Earnings Call Transcript
Ipsen S.A. 2025 Q3 - Results - Earnings Call Presentation
2025-10-22. The following slide deck was published by Ipsen S.A.
Ipsen S.A. reports Q3 results; upgrades FY outlook
Ipsen Reports Positive Phase II Data For IPN10200 In Glabellar Lines, Shows Long-Lasting Efficacy
(RTTNews) - Ipsen (IPSEY) announced first aesthetic data for glabellar lines from Stage 1 of its multi-stage, ongoing Phase II LANTIC trial evaluating the internally developed IPN10200. Patients treat...
Ipsen Secures Japanese Approval For Bylvay In Treating Pruritus
(RTTNews) - Ipsen (IPSEY), Friday announced that Japan's Ministry of Health, Labour and Welfare has approved Bylvay also known as odevixibat for the treatment of pruritus associated with progressive f...
Health Canada Approves Bylvay™ (odevixibat) for the treatment of cholestatic pruritus in patients with Alagille Syndrome
Bylvay™ is the first and only medication approved in Canada for the treatment of both Alagille Syndrome and Progressive Familial Intrahepatic Cholestasis TORONTO , Sept. 9, 2025 /CNW/ -- Medison and I...
Ipsen S.A. 2025 Q2 - Results - Earnings Call Presentation
Ipsen S.A. publishes its 2025 Half-Year Report (half-year ended 30 June 2025)
Ipsen S.A. publishes its 2025 Half-Year Report (half-year ended 30 June 2025) Attachment 2025 Half-year Financial Report_Ipsen SA
Ipsen granted EU nod for Exelixis-partnered cancer drug for neuroendocrine tumors
Madrigal, Ipsen, SpringWorks get EU backing for their drugs
Ipsen S.A. - Initiation of the share buy-back program
Regulated information Ipsen initiates a share buy-back program to cover its free employee share-allocation plan PARIS, FRANCE, 2 June 2025 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today that ...
Ipsen S.A. - Annual General Meeting held on 21 May 2025
Annual General Meeting of Ipsen S.A. held on 21 May 2025 All the resolutions submitted to the shareholders' vote have been adopted PARIS, FRANCE, 21 May 2025 - Ipsen (Euronext: IPN; ADR: IPSEY) announ...
Ipsen S.A. - Formalities for making available and consulting preparatory documents to the 2025 Annual General Meeting
Information relating to the holding of the Combined Shareholders' Meeting of 21 May 2025 of Ipsen S.A. Formalities for making available and consulting preparatory documents to the Meeting PARIS, FRANC...
Ipsen S.A. (IPSEY) Q1 2025 Earnings Call Transcript
Ipsen S.A. reports Q1 results
Ipsen delivers strong sales in the first quarter 2025 and confirms its full-year guidance
PARIS, FRANCE, 16 April 2025 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-care biopharmaceutical company, today presents sales for the first quarter of 2025.